Get the Stockscreener App
11.60
1.24%
0.13
Benitec Biopharma Inc stock is traded at $11.60, with a volume of 13,227.
It is up +1.24% in the last 24 hours and down -6.13% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$11.47
Open:
$11.6
24h Volume:
13,227
Relative Volume:
0.12
Market Cap:
$398.85M
Revenue:
$7,000
Net Income/Loss:
$-41.54M
P/E Ratio:
-12.49
EPS:
-0.929
Net Cash Flow:
$-20.57M
1W Performance:
-2.99%
1M Performance:
-6.13%
6M Performance:
-7.47%
1Y Performance:
+3.86%
1-Day Range:
$11.15
$11.79
1-Week Range:
$11.10
$12.18
52-Week Range:
$9.85
$16.76
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
11.61 | 394.04M | 7,000 | -41.54M | -20.57M | -0.929 |
VRTX
Vertex Pharmaceuticals Inc
|
482.82 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.27 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
896.23 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.56 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
Benitec Biopharma Inc (BNTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BNTC|Benitec Biopharma Inc|Price:11.470|Chg%:+0.030 - TradingKey
TradingKey - TradingKey
Benitec Biopharma Inc (BNTC) Institutional Confidence - TradingKey
Benitec Biopharma Inc (BNTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
(BNTC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BNTC Q2 2026 Earnings: Narrowed Loss Beats Expectations Amid Pipeline ProgressEarnings Trend Analysis - dars.gov.et
BNTC Q2 2026 Earnings: Narrower Loss Exceeds Expectations; Stock Slightly LowerEarnings Trend Analysis - dars.gov.et
Price to sales forward of Benitec Biopharma Inc. – NASDAQ:BNTC - TradingView
BNTCBenitec Biopharma Inc Latest SEC Filings - Finviz
BNTC Stock Price, Quote & Chart - ChartMill
Form 4 Benitec Biopharma Ltd ADR For: 30 June By Investing.com - Investing.com Nigeria
Responsive Playbooks and the BNTC Inflection - Stock Traders Daily
Benitec Biopharma (NASDAQ: BNTC) director gifts 51,813 shares to donor-advised fund - Stock Titan
Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 2000 Value Benchmark - marketscreener.com
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Microcap Value Benchmark Index - marketscreener.com
Benitec Biopharma Inc.(NasdaqCM:BNTC) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Benitec Biopharma Inc.(NasdaqCM: BNTC) added to Russell 3000E Value Benchmark - marketscreener.com
Benitec Biopharma Inc Actuals & Estimates (NASDAQ:BNTC) - TradingView
BNTC Forecast — Price Target — Prediction for 2027 - TradingView
Benitec Biopharma Inc (BNTC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Benitec Biopharma Inc (BNTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BNTC Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentGeographic Revenue Trends - dars.gov.et
Understanding the Setup: (BNTC) and Scalable Risk - Stock Traders Daily
Benitec Biopharma Inc (BNTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Benitec Biopharma Inc (BNTC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Benitec Biopharma Inc (BNTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Benitec Biopharma Inc (BNTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Benitec Biopharma (BNTC) Faces Downgrade Amid Uncertainty - GuruFocus
Guggenheim Downgrades Benitec Biopharma(BNTC.US) to Hold Rating - Moomoo
The Technical Signals Behind (BNTC) That Institutions Follow - Stock Traders Daily
BNTC Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Clinical ProgressInterim Report - newsline.com
Benitec Biopharma (BNTC) Slides 2.22% as Shares Approach Critical SupportEarnings Sentiment - dars.gov.et
Benitec Biopharma (BNTC) Stays Flat: Technical Trading Range Defines Near-Term OutlookGamma Flip Level - The Legal Advocate
BNTC Q1 2026 Earnings: Narrower-than-expected loss highlights controlled spendingEarnings Beat Streak - dars.gov.et
Benitec Biopharma Announces Board Changes and New Director - The Globe and Mail
Benitec BiopharmaCFO Megan Boston Resigns From Board Effective May 22, 2026 - TradingView
Benitec Biopharma Inc. Announces Board Changes, Effective May 22, 2026 - marketscreener.com
Benitec Biopharma (NASDAQ: BNTC) adds director as CFO exits board role - Stock Titan
Benitec Biopharma (BNTC) director option grant benefits Suvretta-managed funds - Stock Titan
Benitec Biopharma (BNTC) director David Friedman files initial Form 3 - Stock Titan
Precision Trading with Benitec Biopharma Inc. (BNTC) Risk Zones - Stock Traders Daily
Benitec Biopharma | 4: Statement of changes in beneficial ownership of securities-Director Friedman David Matthew - Moomoo
Benitec Biopharma (BNTC) Edges Higher Amid Steady TradingGolden Cross - The Legal Advocate
H.C. Wainwright Maintains Benitec Biopharma(BNTC.US) With Buy Rating, Maintains Target Price $32 - Moomoo
Benitec Biopharma’s SWOT analysis: gene therapy stock shows clinical promise By Investing.com - Investing.com South Africa
Benitec Biopharma’s SWOT analysis: gene therapy stock shows clinical promise - Investing.com Nigeria
Citizens reiterates Benitec BioPharma stock rating on dose data By Investing.com - Investing.com Canada
BNTC News | BENITEC BIOPHARMA INC (NASDAQ:BNTC) - ChartMill
Technical Reactions to BNTC Trends in Macro Strategies - Stock Traders Daily
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Benitec Biopharma Inc Stock (BNTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '25 |
Buy |
12.85 |
50,000 |
642,500 |
9,620,075 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 26 '25 |
Buy |
13.10 |
16,836 |
220,552 |
9,634,395 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 22 '25 |
Buy |
12.08 |
19,542 |
236,067 |
9,577,475 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 19 '25 |
Buy |
11.48 |
16,384 |
188,088 |
9,560,825 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 18 '25 |
Buy |
11.24 |
10,215 |
114,817 |
9,546,875 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 07 '25 |
Buy |
13.50 |
1,481,481 |
19,999,994 |
9,538,175 |
0.58%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):